Poster: Assess Targeted I/O Agents with PBMC-Humanized Models

Establishment and Application of a Panel of PBMC-Humanized Mouse Tumor Models in Immuno-Oncology and Targeted Cancer Immunotherapy

Lan Zhang, Ying Jin, Haochen Wu, Fei Chen, Lianqi Zhao, Xiaoyu An, Weibin Tan*, Xiaoyan Fu*, Meng Qiao, Qian Shi, and WenQing Yang

*Taicang Blood Center, Taicang, Suzhou, P.R. China

There is an increasing need for fast, reliable, and cost-effective immunocompetent models for preclinical drug development. This includes targeted cancer immunotherapies, such as bispecific antibodies.

To help progress your targeted immunotherapy programs, we’ve developed a panel of PBMC-humanized mouse tumor models. You can evaluate a wide range of immuno-oncology agents with these models, including human-origin bispecific antibodies as well as immune checkpoint inhibitors and immunomodulators.

This poster details the development, characterization, and optimization of a selection of models from this panel. These models overexpress a range of tumor antigens e.g. EGFR, CD47, Braf, PD-L1, etc. for targeted therapy development.

Read this Poster to Discover:

• How PBMC-humanized models, developed with specific tumor antigen targeting strategies, can progress your immunotherapy and bispecific antibody development
  
  
• That more than 20 PBMC-humanized tumor models have been developed already, with GvHD managed through optimizing immune and cancer cell inoculation
  
  
• Model validation with benchmark immune checkpoint inhibitors or immunomodulatory agents, showing that antitumor efficacy is donor dependent

Download the Poster Now!